Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. 

 Financial ResultsNet cash used in operating activities for the Year

$3.9 millionCash position at the end of the Year

$5.1 millionReported loss

$4.1 million 

Operational HighlightsCAVATAK™ Phase II CALM Melanoma Clinical Trial (USA) Highlights include:

  • CAVATAK™ presented at the American Society of Clinical Oncologists conference in June 2013 and the World Melanoma Congress in July 2013 to a global oncology audience.
  • Key milestone achieved with enrolment of the 35th patient. Independent Data Monitoring Committee reported that CAVATAK™ had met safety and tolerability criteria.
  • Patient enrolment now at 10 prestigious US cancer clinics, with acceleration since early 2013. Aiming for full recruitment by the end of the calendar year.
  • 23 patients have reached assessment point against the trial's primary endpoint of immune related Progression Free Survival (irPFS) at 6 months. Interim results very promising with 8 of 23 patients having achieved the primary endpoint. Trial target is 10 of 54 evaluable patients achieving primary endpoint.
  • 2 complete and 6 partial tumour responses from 30 assessable patients. Anti-cancer activity demonstrated in non-injected (metastatic or secondary) as well as the injected tumours.
  • CAVATAK™ Phase I studies completed (Australia)

  • Intravenously administered CAVATAK™ well tolerated in late stage cancer patients.
  • Some evidence of tumour stabilization in intravenous study after only a single dose.
  • Sound basis for a multi-dose intravenous Phase 1 / 2 trial (our STORM study).
  • CAVATAK™ Preclinical studies completed (Australia and the UK)

  • Broad anti-cancer activity of CAVATAK™ demonstrated in preclinical setting.
  • Synergistic effect from the combination of CAVATAK™ and Docetaxel.  Potential combination therapy.
  • Combination with either radiation or chemotherapy resulted in more potent anticancer activity in bladder cancer cell lines than radiation or chemotherapy alone.
  • Potent anti-cancer activity in chronic lymphocytic leukaemia (CLL) cell lines.
  • "The 2013 financial year has been one of outstanding progress at Viralytics, which leaves us well positioned to further develop the business in the coming year," said Dr. Malcolm McColl, Chief Executive Officer of Viralytics. "We have achieved key milestones in our Phase 2 CALM study, with interim results demonstrating promising anti-cancer activity. We also had a number of excellent outcomes in our Phase 1 and preclinical programs, demonstrating the broad anti-cancer activity of CAVATAK™.  Our focus is to maintain momentum in clinical development and translate this progress into valuable commercial outcomes."

    About Viralytics Ltd:
    Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAK™ is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US.  Viralytics also plans to commence a Phase 1/2 study of CAVATAK™ delivered intravenously in patients with melanoma, prostate, lung or metastatic bladder cancers prior to the end of 2013 (the STORM study).

    Based in Sydney Australia, Viralytics is listed on the Australian Securities Exchange (ASX: VLA) while its ADRs also trade under VRACY on the US OTCQX market.  For more information on the company, please visit http://www.viralytics.com

     For Viralytics Ltd:US Investor Contacts:Dr. Malcolm McColl

    +61 2 8889 3672

    Joshua Drumm, Ph.D. / Jason Rando

    Tiberend Strategic Advisors, Inc.

    212.827.0020

    jdrumm@tiberend.com

    jrando@tiberend.com 


    '/>"/>
    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
    (Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
    (Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
    Breaking Medicine Technology:
    (Date:5/19/2017)... ... 18, 2017 , ... ML Billing, 2016 Billing Company of the Year ... in large group practices, is pleased to announce their 30th anniversary. Not only has ... standard in all aspects of full-service medical billing. This has allowed ML Billing to ...
    (Date:5/19/2017)... ... May 18, 2017 , ... ... who served eight American presidents of both political parties, will become the 9th ... General Colin L. Powell, USA (Retired) as Chairman in May, 2018. , Secretary ...
    (Date:5/18/2017)... MD (PRWEB) , ... May 18, 2017 , ... Dr. ... disease treatment and educating her community on the link between this condition and serious ... have moderate to severe periodontal disease in Annapolis, MD, and seeking treatment ...
    (Date:5/18/2017)... ... May 18, 2017 , ... Summit BHC (Summit), ... acquisition of English Mountain Recovery. Located in Sevierville, Tennessee approximately 30 miles ... in the state and brings the Company’s total number of operating facilities to ...
    (Date:5/18/2017)... Boulder, CO (PRWEB) , ... May 18, 2017 , ... ... spotlight on low-performing schools. A remedy offered to “turn around” low-performance in school districts ... elsewhere. , School Closure as a Strategy to Remedy Low Performance , authored ...
    Breaking Medicine News(10 mins):